Comparative Study
doi: 10.1136/bmj.280.6217.833.Study of information submitted by drug companies to licensing authorities
- PMID:7370687
- PMCID: PMC1601011
- DOI: 10.1136/bmj.280.6217.833
Item in Clipboard
Comparative Study
Study of information submitted by drug companies to licensing authorities
E Hemminki. Br Med J..
Display options
Format
Display options
Format
Abstract
Reports of clinical trials included in applications submitted by drug companies to licensing authorities in Finland and Sweden in four different years were studied. Many reports were submitted, but most of the trials were uncontrolled and of poor quality. Many of the reports were unpublished, and thus, as the submissions are secret, were not available to doctors. These unpublished reports were in most respects as valuable as the published reports. Most of the reports included some information about adverse effects; the information was often deficient, but skilled analysis might increase its value. This study provides support for those who want to see public disclosure of the reports of trials submitted in licensing applications.
Similar articles
- Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish control authorities.Hemminki E.Hemminki E.Eur J Clin Pharmacol. 1981 Feb;19(3):157-65. doi: 10.1007/BF00561942.Eur J Clin Pharmacol. 1981.PMID:7215412
- Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.Hemminki E, McPherson K.Hemminki E, et al.Lancet. 2000 Feb 12;355(9203):566-9. doi: 10.1016/S0140-6736(99)03432-7.Lancet. 2000.PMID:10683020
- Psychotropic drug registration in the Scandinavian countries: the role of clinical trials.Hemminki E, Falkum E.Hemminki E, et al.Soc Sci Med Med Psychol Med Sociol. 1980 Dec;14A(6):547-59. doi: 10.1016/0160-7979(80)90057-0.Soc Sci Med Med Psychol Med Sociol. 1980.PMID:7209629No abstract available.
- [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].Kock M, Thomsen MK.Kock M, et al.Ugeskr Laeger. 2003 Apr 14;165(16):1649-52.Ugeskr Laeger. 2003.PMID:12756820Review.Danish.
- Interactions between physicians and the pharmaceutical industry: what does the literature say?Lexchin J.Lexchin J.CMAJ. 1993 Nov 15;149(10):1401-7.CMAJ. 1993.PMID:8221424Free PMC article.Review.
Cited by
- Journal notes.Beatty WK.Beatty WK.Bull Med Libr Assoc. 1981 Jan;69(1):55-8.Bull Med Libr Assoc. 1981.PMID:16017801Free PMC article.No abstract available.
- The safety of acupuncture during pregnancy: a systematic review.Park J, Sohn Y, White AR, Lee H.Park J, et al.Acupunct Med. 2014 Jun;32(3):257-66. doi: 10.1136/acupmed-2013-010480. Epub 2014 Feb 19.Acupunct Med. 2014.PMID:24554789Free PMC article.Review.
- The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration.Turner L, Boutron I, Hróbjartsson A, Altman DG, Moher D.Turner L, et al.Syst Rev. 2013 Sep 23;2:79. doi: 10.1186/2046-4053-2-79.Syst Rev. 2013.PMID:24059942Free PMC article.Review.No abstract available.
- Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols.Chan AW, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG.Chan AW, et al.BMJ. 2008 Dec 4;337:a2299. doi: 10.1136/bmj.a2299.BMJ. 2008.PMID:19056791Free PMC article.
- Clinical and economic burden of adverse drug reactions.Sultana J, Cutroneo P, Trifirò G.Sultana J, et al.J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S73-7. doi: 10.4103/0976-500X.120957.J Pharmacol Pharmacother. 2013.PMID:24347988Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical